News + Press Releases
Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update
Development Program Highlights and Anticipated 2024 Milestones: Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy study recruiting across the United States.
Fueling Progress, One Insight at a Time
Dive into the latest news, peer-reviewed publications, and clinical trials shaping the future of women’s health.
News + Press Releases
Press Release: Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update
Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women’s Health Solutions, and Multiple Near-Term Potential Catalysts
March 26, 2026
News + Press Releases
Press Release: On National Viagra Day, Women Finally Claim Their Turn
DARE to PLAY™ Sildenafil Cream Is Rewriting the Story of Sexual Health — For Her
March 23, 2026
News + Press Releases
Press Release: Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026
The webcast will be archived and available for replay until April 9, 2026.
March 20, 2026
News + Press Releases
Press Release: Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update
Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women’s Health Solutions, and Multiple Near-Term Potential Catalysts
March 26, 2026
News + Press Releases
Press Release: On National Viagra Day, Women Finally Claim Their Turn
DARE to PLAY™ Sildenafil Cream Is Rewriting the Story of Sexual Health — For Her
March 23, 2026
News + Press Releases
Press Release: Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026
The webcast will be archived and available for replay until April 9, 2026.
March 20, 2026
